PUBLISHER: TechNavio | PRODUCT CODE: 2172604
PUBLISHER: TechNavio | PRODUCT CODE: 2172604
Global Krabbe Disease Treatment Market 2026-2030
The global krabbe disease treatment market is forecasted to grow by USD 469.1 mn during 2025-2030, accelerating at a CAGR of 7.2% during the forecast period. The report on the global krabbe disease treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by broad adoption of comprehensive neonatal diagnostics, acceleration of clinical trials for small molecule therapeutics, corporate consolidation in genetic medicines.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 6.9% |
| CAGR | 7.2% |
| Incremental Value | $469.1 mn |
Technavio's global krabbe disease treatment market is segmented as below:
By Therapy
- Anticonvulsants
- Muscle relaxants
- HSCT
- Others
By Route Of Administration
- Intravenous
- Intracerebroventricular
By Type
- Early infantile Krabbe disease
- Juvenile Krabbe disease
- Late infantile Krabbe disease
- Adult-onset Krabbe disease
Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the accelerated approvals and small molecule pipeline expansion as one of the prime reasons driving the global krabbe disease treatment market growth during the next few years. Also, expanded integration of multiplex newborn screening technologies and biopharma and patient advocacy collaborations will lead to sizable demand in the market.
The report on the global krabbe disease treatment market covers the following areas:
- Global krabbe disease treatment market sizing
- Global krabbe disease treatment market forecast
- Global krabbe disease treatment market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global krabbe disease treatment market vendors that include AbbVie Inc., Amneal Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Bristol Myers Squibb Co., Cipla Inc., Daiichi Sankyo Co. Ltd., Hikma Pharmaceuticals Plc, Jazz Pharmaceuticals Plc, Johnson and Johnson, Lupin Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries, Takeda Pharmaceutical Ltd., Teva Pharmaceutical Ltd., UCB SA, Vertex Pharmaceuticals Inc., Zydus Lifesciences Ltd.. Also, the global krabbe disease treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Therapy
- Executive Summary - Chart on Market Segmentation by Route of Administration
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Global Krabbe Disease Treatment Market 2020 - 2024
- Historic Market Size - Data Table on Global Krabbe Disease Treatment Market 2020 - 2024 ($ million)
- 5.2 Therapy segment analysis 2020 - 2024
- Historic Market Size - Therapy Segment 2020 - 2024 ($ million)
- 5.3 Route of Administration segment analysis 2020 - 2024
- Historic Market Size - Route of Administration Segment 2020 - 2024 ($ million)
- 5.4 Type segment analysis 2020 - 2024
- Historic Market Size - Type Segment 2020 - 2024 ($ million)
- 5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
- 5.6 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI on Global Krabbe Disease Treatment Market
- 6.2 Impact of Geopolitical Conflicts on Global Krabbe Disease Treatment Market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by Therapy
- 8.1 Market segments
- 8.2 Comparison by Therapy
- 8.3 Anticonvulsants - Market size and forecast 2025-2030
- 8.4 Muscle relaxants - Market size and forecast 2025-2030
- 8.5 HSCT - Market size and forecast 2025-2030
- 8.6 Others - Market size and forecast 2025-2030
- 8.7 Market opportunity by Therapy
- Market opportunity by Therapy ($ million)
9 Market Segmentation by Route of Administration
- 9.1 Market segments
- 9.2 Comparison by Route of Administration
- 9.3 Intravenous - Market size and forecast 2025-2030
- 9.4 Intracerebroventricular - Market size and forecast 2025-2030
- 9.5 Market opportunity by Route of Administration
- Market opportunity by Route of Administration ($ million)
10 Market Segmentation by Type
- 10.1 Market segments
- 10.2 Comparison by Type
- 10.3 Early infantile Krabbe disease - Market size and forecast 2025-2030
- 10.4 Juvenile Krabbe disease - Market size and forecast 2025-2030
- 10.5 Late infantile Krabbe disease - Market size and forecast 2025-2030
- 10.6 Adult-onset Krabbe disease - Market size and forecast 2025-2030
- 10.7 Market opportunity by Type
- Market opportunity by Type ($ million)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 North America - Market size and forecast 2025-2030
- 12.3.1 US - Market size and forecast 2025-2030
- 12.3.2 Canada - Market size and forecast 2025-2030
- 12.3.3 Mexico - Market size and forecast 2025-2030
- 12.4 Europe - Market size and forecast 2025-2030
- 12.4.1 Germany - Market size and forecast 2025-2030
- 12.4.2 UK - Market size and forecast 2025-2030
- 12.4.3 France - Market size and forecast 2025-2030
- 12.4.4 Italy - Market size and forecast 2025-2030
- 12.4.5 Spain - Market size and forecast 2025-2030
- 12.4.6 The Netherlands - Market size and forecast 2025-2030
- 12.5 Asia - Market size and forecast 2025-2030
- 12.5.1 China - Market size and forecast 2025-2030
- 12.5.2 India - Market size and forecast 2025-2030
- 12.5.3 Japan - Market size and forecast 2025-2030
- 12.5.4 South Korea - Market size and forecast 2025-2030
- 12.5.5 Indonesia - Market size and forecast 2025-2030
- 12.5.6 Thailand - Market size and forecast 2025-2030
- 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 12.6.1 Brazil - Market size and forecast 2025-2030
- 12.6.2 Australia - Market size and forecast 2025-2030
- 12.6.3 Saudi Arabia - Market size and forecast 2025-2030
- 12.6.4 UAE - Market size and forecast 2025-2030
- 12.6.5 Argentina - Market size and forecast 2025-2030
- 12.6.6 Turkey - Market size and forecast 2025-2030
- 12.6.7 South Africa - Market size and forecast 2025-2030
- 12.6.8 Israel - Market size and forecast 2025-2030
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Broad adoption of comprehensive neonatal diagnostics
- Acceleration of clinical trials for small molecule therapeutics
- Corporate consolidation in genetic medicines
- 13.2 Market challenges
- High costs and complex gene therapy manufacturing
- Stringent regulations and complex clinical trials
- Gaps in newborn screening and diagnosis
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 13.4 Market opportunities
- Accelerated approvals and small molecule pipeline expansion
- Expanded integration of multiplex newborn screening technologies
- Biopharma and patient advocacy collaborations
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- Companies covered
- 15.2 Company ranking index
- Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 AbbVie Inc.
- AbbVie Inc. - Overview
- AbbVie Inc. - Business segments
- AbbVie Inc. - Key news
- AbbVie Inc. - Key offerings
- AbbVie Inc. - Segment focus
- SWOT
- 15.5 Astellas Pharma Inc.
- Astellas Pharma Inc. - Overview
- Astellas Pharma Inc. - Product / Service
- Astellas Pharma Inc. - Key news
- Astellas Pharma Inc. - Key offerings
- SWOT
- 15.6 AstraZeneca Plc
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Business segments
- AstraZeneca Plc - Key news
- AstraZeneca Plc - Key offerings
- AstraZeneca Plc - Segment focus
- SWOT
- 15.7 Bristol Myers Squibb Co.
- Bristol Myers Squibb Co. - Overview
- Bristol Myers Squibb Co. - Product / Service
- Bristol Myers Squibb Co. - Key news
- Bristol Myers Squibb Co. - Key offerings
- SWOT
- 15.8 Jazz Pharmaceuticals Plc
- Jazz Pharmaceuticals Plc - Overview
- Jazz Pharmaceuticals Plc - Product / Service
- Jazz Pharmaceuticals Plc - Key news
- Jazz Pharmaceuticals Plc - Key offerings
- SWOT
- 15.9 Johnson and Johnson
- Johnson and Johnson - Overview
- Johnson and Johnson - Business segments
- Johnson and Johnson - Key news
- Johnson and Johnson - Key offerings
- Johnson and Johnson - Segment focus
- SWOT
- 15.10 Merck and Co. Inc.
- Merck and Co. Inc. - Overview
- Merck and Co. Inc. - Business segments
- Merck and Co. Inc. - Key news
- Merck and Co. Inc. - Key offerings
- Merck and Co. Inc. - Segment focus
- SWOT
- 15.11 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
- 15.12 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Segment focus
- SWOT
- 15.13 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT
- 15.14 Sun Pharmaceutical Industries
- Sun Pharmaceutical Industries - Overview
- Sun Pharmaceutical Industries - Business segments
- Sun Pharmaceutical Industries - Key news
- Sun Pharmaceutical Industries - Key offerings
- Sun Pharmaceutical Industries - Segment focus
- SWOT
- 15.15 Takeda Pharmaceutical Ltd.
- Takeda Pharmaceutical Ltd. - Overview
- Takeda Pharmaceutical Ltd. - Business segments
- Takeda Pharmaceutical Ltd. - Key news
- Takeda Pharmaceutical Ltd. - Key offerings
- Takeda Pharmaceutical Ltd. - Segment focus
- SWOT
- 15.16 Teva Pharmaceutical Ltd.
- Teva Pharmaceutical Ltd. - Overview
- Teva Pharmaceutical Ltd. - Business segments
- Teva Pharmaceutical Ltd. - Key news
- Teva Pharmaceutical Ltd. - Key offerings
- Teva Pharmaceutical Ltd. - Segment focus
- SWOT
- 15.17 UCB SA
- UCB SA - Overview
- UCB SA - Product / Service
- UCB SA - Key news
- UCB SA - Key offerings
- SWOT
- 15.18 Zydus Lifesciences Ltd.
- Zydus Lifesciences Ltd. - Overview
- Zydus Lifesciences Ltd. - Business segments
- Zydus Lifesciences Ltd. - Key news
- Zydus Lifesciences Ltd. - Key offerings
- Zydus Lifesciences Ltd. - Segment focus
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- Research methodology
- 16.5 Data procurement
- Information sources
- 16.6 Data validation
- Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
- List of abbreviations
